Vocabria and Rekambys win EC approval for HIV in adolescents

The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) and Johnson & Johnson’s (NYSE: JNJ) Rekambys (rilpivirine long-acting injections) to treat HIV-1 infection in adolescents of 12 years of age and older and weighing at least 35 kg who are virologically suppressed.

This combination is the first and only complete long-acting injectable regimen for the treatment of HIV, and was approved in the European Union for the treatment of HIV-1 in adults who are virologically suppressed, in December 2020.

 As of 2023, there were 1.55 million people aged 10 to 19 years around the world living with HIV. People in this age bracket typically have lower reported treatment coverage, adherence to treatment and viral suppression rates than older age groups.